Aurobindo Pharma’s arm gets 2 observations from USFDA

19 Jan 2023 Evaluate

The United States Food and Drug Administration (USFDA) has inspected Aurobindo Pharma's wholly owned subsidiary, APL Health Care's Unit I & III, an Orals (Tablets, Capsules and Soft gel Capsules) and Derma Manufacturing facility located at Jadcherla, Mahabub Nagar District, Telangana, from January 9 to January 18, 2023.

At the end of the inspection, the company has been issued a 'Form 483' with 2 observations. The observations are procedural in nature. The company will respond to the USFDA within the stipulated timelines and work closely with USFDA to close the observations at the earliest.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×